HK1062266A1 - Combination comprising a signal transduction inhibitor and an epothilone derivative - Google Patents

Combination comprising a signal transduction inhibitor and an epothilone derivative

Info

Publication number
HK1062266A1
HK1062266A1 HK04105220.7A HK04105220A HK1062266A1 HK 1062266 A1 HK1062266 A1 HK 1062266A1 HK 04105220 A HK04105220 A HK 04105220A HK 1062266 A1 HK1062266 A1 HK 1062266A1
Authority
HK
Hong Kong
Prior art keywords
combination
signal transduction
transduction inhibitor
epothilone derivative
derivative
Prior art date
Application number
HK04105220.7A
Other languages
English (en)
Inventor
Elisabeth Buchdunger
Carl-Henrik Heldin
Arne Oestman
Kristian Pietras
Terence O'reilly
John David Rothermel
Peter Traxler
Markus Wartmann
Ralf Brandt
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0104840.4A external-priority patent/GB0104840D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HK1062266A1 publication Critical patent/HK1062266A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK04105220.7A 2001-02-27 2004-07-15 Combination comprising a signal transduction inhibitor and an epothilone derivative HK1062266A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0104840.4A GB0104840D0 (en) 2001-02-27 2001-02-27 Use of organic compounds
US33904001P 2001-10-30 2001-10-30
PCT/EP2002/002049 WO2002067941A2 (en) 2001-02-27 2002-02-26 Combination comprising a signal transduction inhibitor and an epothilone derivative

Publications (1)

Publication Number Publication Date
HK1062266A1 true HK1062266A1 (en) 2004-10-29

Family

ID=26245767

Family Applications (1)

Application Number Title Priority Date Filing Date
HK04105220.7A HK1062266A1 (en) 2001-02-27 2004-07-15 Combination comprising a signal transduction inhibitor and an epothilone derivative

Country Status (23)

Country Link
US (1) US7723339B2 (xx)
EP (1) EP1385522B1 (xx)
JP (1) JP4499359B2 (xx)
KR (1) KR100848197B1 (xx)
CN (1) CN1511036B (xx)
AT (1) ATE434438T1 (xx)
AU (1) AU2002308218B2 (xx)
BR (1) BR0207649A (xx)
CA (1) CA2439268C (xx)
CY (1) CY1109347T1 (xx)
DE (1) DE60232719D1 (xx)
DK (1) DK1385522T3 (xx)
ES (1) ES2326264T3 (xx)
HK (1) HK1062266A1 (xx)
IL (2) IL157466A0 (xx)
MX (1) MXPA03007729A (xx)
NO (1) NO325416B1 (xx)
NZ (1) NZ527764A (xx)
PL (1) PL207197B1 (xx)
PT (1) PT1385522E (xx)
RU (1) RU2313345C2 (xx)
SK (1) SK287489B6 (xx)
WO (1) WO2002067941A2 (xx)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1386922B1 (en) * 1996-12-03 2012-04-11 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereof, analogues and uses thereof
PL368973A1 (en) 2001-03-14 2005-04-04 Bristol-Myers Squibb Company Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
HUP0400038A3 (en) * 2001-05-16 2007-05-29 Novartis Ag Combination comprising n-{5-[4-{-methyl-piperazino-methyl)-benzoylamino]-2-methylphenyl}-4-(3-pyridyl)-2pyrimidine-amine and a chemotherapeutic agent
EP1704863A3 (en) * 2001-05-16 2010-11-24 Novartis AG Combination comprising N-5-4-(4-Methyl-Piperazino-Methyl-)Benzoyla Mido]-2-Methylphenyl -4-(3-Pyridyl)-2Phyrimidine-amine and a chemotherapeutic agent
WO2003037897A2 (en) * 2001-10-29 2003-05-08 Novartis Ag Use of 7h-pyrrolo[2,3-d]pyrimidine derivatives in the treatment of solid tumor diseases
MXPA05002113A (es) 2002-08-23 2005-06-03 Sloan Kettering Inst Cancer Sintesis de epotilonas, intermediarios para ellas, analogos y usos de los mismos.
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US20050171167A1 (en) * 2003-11-04 2005-08-04 Haby Thomas A. Process and formulation containing epothilones and analogs thereof
JO2596B1 (en) * 2004-11-30 2011-02-27 نوفارتيس ايه جي Compositions include epothelones and tyrosine protein kinase inhibitors and their pharmaceutical uses
US20060121511A1 (en) 2004-11-30 2006-06-08 Hyerim Lee Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents
CN101535492A (zh) 2005-02-11 2009-09-16 南加州大学 表达含有二硫键的蛋白质的方法
EP2029156A4 (en) * 2006-05-01 2010-07-21 Univ Southern California POLY THERAPY FOR TREATING CANCER
WO2010056901A2 (en) 2008-11-13 2010-05-20 University Of Southern California Method of expressing proteins with disulfide bridges with enhanced yields and activity
WO2010108503A1 (en) 2009-03-24 2010-09-30 Life & Brain Gmbh Promotion of neuronal integration in neural stem cell grafts
CN105797168A (zh) 2010-05-18 2016-07-27 天蓝制药公司 用于治疗自身免疫性疾病或其它疾病的组合物和方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3040121B2 (ja) * 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
DE4138042C2 (de) 1991-11-19 1993-10-14 Biotechnolog Forschung Gmbh Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel
TW225528B (xx) 1992-04-03 1994-06-21 Ciba Geigy Ag
PT836605E (pt) * 1995-07-06 2002-07-31 Novartis Ag Pirrolopirimidinas e processos para a sua preparacao
CA2269118C (en) 1996-11-18 2012-05-29 Gesellschaft Fur Biotechnologische Forschung Mbh (Gbf) Epothilone c, d, e and f, production process, and their use as cytostatic as well as phytosanitary agents
CO4940418A1 (es) * 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
US6302838B1 (en) * 1998-02-25 2001-10-16 Novartis Ag Cancer treatment with epothilones
WO2000000485A1 (de) * 1998-06-30 2000-01-06 Schering Aktiengesellschaft Epothilon-derivate, verfahren zu deren herstellung, zwischenprodukte und ihre pharmazeutische verwendung
CN1340053A (zh) * 1999-02-11 2002-03-13 舍林股份公司 依泊昔酮衍生物、其制备方法及药物用途
DE19908760A1 (de) * 1999-02-18 2000-08-24 Schering Ag Neue Epothilon-Derivate, Verfahren zu deren Herstellung und ihre pharmazeutische Verwendung

Also Published As

Publication number Publication date
NO325416B1 (no) 2008-04-21
CN1511036A (zh) 2004-07-07
NZ527764A (en) 2006-01-27
PL207197B1 (pl) 2010-11-30
US7723339B2 (en) 2010-05-25
DE60232719D1 (de) 2009-08-06
PL363288A1 (en) 2004-11-15
EP1385522B1 (en) 2009-06-24
CY1109347T1 (el) 2014-07-02
IL157466A (en) 2012-04-30
WO2002067941A8 (en) 2003-12-18
US20040132754A1 (en) 2004-07-08
PT1385522E (pt) 2009-09-04
ES2326264T3 (es) 2009-10-06
BR0207649A (pt) 2004-03-09
MXPA03007729A (es) 2003-12-04
SK287489B6 (sk) 2010-11-08
CA2439268C (en) 2010-01-19
WO2002067941A3 (en) 2003-11-20
IL157466A0 (en) 2004-03-28
WO2002067941A2 (en) 2002-09-06
RU2313345C2 (ru) 2007-12-27
CN1511036B (zh) 2010-05-05
EP1385522A2 (en) 2004-02-04
SK10712003A3 (sk) 2004-02-03
JP4499359B2 (ja) 2010-07-07
CA2439268A1 (en) 2002-09-06
AU2002308218B2 (en) 2005-11-10
KR100848197B1 (ko) 2008-07-24
DK1385522T3 (da) 2009-10-12
ATE434438T1 (de) 2009-07-15
RU2003127392A (ru) 2005-03-27
NO20033769D0 (no) 2003-08-25
JP2004527493A (ja) 2004-09-09
KR20040025900A (ko) 2004-03-26
NO20033769L (no) 2003-08-25

Similar Documents

Publication Publication Date Title
CY1109347T1 (el) Συνδυασμος που αποτελειται απο εναν αναστολεα μεταλλαγης σηματος και ενα παραγωγο εποθιλονης
IL176070A0 (en) COMBINATION OF (a) N-{5-[4-(4-METHYL-PIPERAZINO-METHYL)-BENZOYLAMIDO]-2-METHYLPHENYL}-4-(3-PYRIDYL)-2-PYRIMIDINE-AMINE AND (b) AT LEAST ONE HYPUSINATION INHIBITOR AND THE USE THEREOF
CY2022009I2 (el) Διυδροναφθυριδινες και σχετικες ενωσεις χρησιμες ως αναστολεις κινασης για τη θεραπεια πολλαπλασιαστικων ασθενειων
NO20076323L (no) Kombinasjon omfattende N-{5-[4-(4-metylpiperazinometyl)-benzoylamido]-2-metyl-fenyl}-4-(3-pyridyl)-2-pyrimidinamin og en aromataseinhibitor, anvendelse av kombinasjonen samt farmasøytisk preparat
NO20044093L (no) N-{5-[4-(4-metylpiperazinometyl)-benzoylamido]-2-metylfenyl}-4-(3-pyridyl)-2-pyrimidinamin belagte stenter
AU2003259521A8 (en) Combination of a) n-{5-(4-(4-methyl-piperazino-methyl)-benzoylamido)-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine and b) a histone deacetylase inhibitor for the treatment of leukemia
NO20022864L (no) Aminotiazol inhibitorer av syklin uavhengig kinase
NO20023319D0 (no) Substituerte glutarimider og deres anvendelse som inhibitorer av IL-12-produksjonen
EE200300041A (et) Tsükliin-sõltuvate kinaaside N-[5-[[[5-alküül-2-oksasolüül]metüül]tio]-2-tiasolüül]karboksamiidinhibiitorid
ATE339197T1 (de) 4-(4-methylpiperazin-1-ylmethyl)-n-(4-methyl-3- 4-pyrimindin-3-yl)pyrimidin-2-yl-amino)phenyl)- benzamide zur behandlung von ang-ii vermittelt krankheiten
WO2002028829A3 (en) Peptide deformylase inhibitors
SG127737A1 (en) Piperidine and piperazine substituted n-hydroxyformamides as inhibitors of metalloproteinases
AU2002353147A8 (en) 3-(phenyl-alkoxy)-5-(phenyl)-pyridine derivatives and related compounds as kinase inhibitors for the treatment of cancer
NO20023785D0 (no) Vanndispergerbar formulering av paroxetin
NO20034124L (no) Sammensetning av et taxan og en cyclinavhengig kinaseinhibitor
ATE476183T1 (de) Verfahren zur behandlung von soliden tumoren einschliesslich der verabreichung einer kombination mit imatinib und einem effluxpumpenhemmer
ATE348615T1 (de) 2-(4-(2-hydroxymethyl-phenylamino)-piperidin-1- yl)-n-(9h-carbazol-3-yl) - acetamid derivate und verwandte verbindungen als neuropeptide y5 (npy5) liganden zur behandlung von fettleibigkeit
EE200000638A (et) 1-(6-kloronaft-2-üülsulfonüül)-4-[4-(4-püridüül)bensoüül]-piperasiini vähendatud osakesesuurusega vorm
HK1062683A1 (en) Synthesis of 4-(piperidyl) (2-pyridyl)methanone-(E)-=-methyloxime and its salts.
SI1436282T1 (en) Synthesis of 4-(piperidyl) (2-pyridyl)methanone-(e)-o-methyloxime and its salts
HUP0401645A3 (en) Alpha crystal form of 4-(4-methyl-piperazine-1-yl-methyl)-n-[4-methyl-3-(4-pyridine-3-yl)-pyrimidine-2-yl-amino]-phenyl)-benzamide monomethanesulfonate

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20140226